Editas Medicine stock trades at EUR 2.46 before Q3 results

Editas Medicine stock traded at 2.46 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4, 2026; investors can follow the real-time quote of Editas Medicine stock.

Clinical program remains central

Editas Medicine is scheduled to report its third-quarter 2026 results before the market opens on Monday, November 9, according to MarketBeat. The company is expected to discuss a period in which investors are focused on the progress of its clinical pipeline and cash use.

In an analysis published October 28, Tickeron said Australian authorities had cleared the Phase 1/2 Strive trial of EDIT-401. The report described the program as Editas Medicine’s first in vivo gene-editing candidate to reach the clinic and noted that Wells Fargo had raised its rating to Overweight while lifting its target from 4 US dollars to 6 US dollars on October 8.

Next milestones for EDIT-401

Editas Medicine expects to begin dosing patients in the Strive trial in Australia and New Zealand, with five clinical sites selected across the two countries, according to the Tickeron analysis. Investors are also watching new preclinical durability data expected at the American Heart Association Scientific Sessions in November and initial safety and tolerability results targeted for the first quarter of 2027.

Editas Medicine and its peers

Editas Medicine is a biotechnology company based in Cambridge, Massachusetts, developing CRISPR-based gene-editing therapies for serious diseases. Its lead program, EDIT-401, targets the LDLR gene for patients with heterozygous familial hypercholesterolemia. The company competes with CRISPR Therapeutics, Intellia Therapeutics and Beam Therapeutics, with Editas focused on a narrower clinical pipeline and in vivo editing applications.

Broader biotechnology sentiment remains relevant as investors assess clinical execution and financing conditions; see the S&P 500 market overview for wider equity-market context.

More news and analyses on Editas Medicine stock are available on the Editas Medicine stock topic page.